Bayer's Baumann Says on Track With Monsanto Filings

The transcript covers Bayer's strong performance, particularly in pharma, and the success of Covestro. It discusses the progress of the Monsanto deal, including regulatory filings and discussions with US and European regulators. The financing strategy, including equity and debt considerations, is outlined. Plans for managing the Covestro stake are detailed, with a focus on optimizing value. The transcript concludes with a discussion on market opportunities and strategic execution.

What is Bayer's strategy regarding its stake in Covestro and how does it plan to manage it?

What are the main themes Bayer is focusing on in its business strategy moving forward?

How does Bayer view the current market conditions for potential mergers and acquisitions?